Table 3, Table 4, Table 5,
and Table 6 provide guidelines for dose modifications
and discontinuation of PEGASYS/
COPEGUS based on laboratory
abnormalities, patient’s depression status, and cardiac status.
Adult Patients
When dose modification of PEGASYS is required for adverse reactions (clinical and/or laboratory), initial dose reduction to 135 mcg (which is 0.75 mL for the vials or adjustment to the corresponding graduation mark for
the prefilled syringes) is recommended.